Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer
Standard
Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. / Maierthaler, Melanie; Benner, Axel; Hoffmeister, Michael; Surowy, Harald; Jansen, Lina; Knebel, Phillip; Chang-Claude, Jenny; Brenner, Hermann; Burwinkel, Barbara.
In: INT J CANCER, Vol. 140, No. 1, 01.01.2017, p. 176-187.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer
AU - Maierthaler, Melanie
AU - Benner, Axel
AU - Hoffmeister, Michael
AU - Surowy, Harald
AU - Jansen, Lina
AU - Knebel, Phillip
AU - Chang-Claude, Jenny
AU - Brenner, Hermann
AU - Burwinkel, Barbara
N1 - © 2016 UICC.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Circulating microRNAs (miRNAs) have been proposed as minimally invasive prognostic markers for various types of cancers, including colorectal cancer (CRC), the third most diagnosed cancer worldwide. We aimed to evaluate the levels of circulating miRNAs that might serve as markers for CRC prognosis and survival. We included plasma samples of 543 CRC patients with stage I-IV disease from a population-based study carried out in Germany. After comprehensive evaluation of current literature, 95 miRNAs were selected and measured with Custom TaqMan® Array MicroRNA Cards. Plasma samples of non-metastatic and metastatic colon cancer patients, each group consisting of ten patients with 'good' and ten patients with 'bad' prognosis were screened. Identified candidate miRNAs were further validated by RT-qPCR in the whole study cohort. The association of the miRNA levels with patients' survival and the prognostic subtypes was analyzed with uni- and multivariate logistic regression and Cox proportional hazards regression models. Increased miR-122 levels were associated with a 'bad' prognostic subtype in metastatic CRC (Odds ratio: 1.563, 95% confidence interval (CI): 1.038-2.347) and a shorter relapse-free survival and overall survival for non-metastatic (Hazard ratio (HR): 1.370, 95% CI: 1.028-1.825; HR: 1.353, 95% CI: 1.002-1.828) and metastatic (HR: 1.264, 95% CI: 1.050-1.520; HR: 1.292, 95% CI: 1.078-1.548) CRC patients. Additionally, several members of the miR-200 family showed associations with patients' prognosis and correlations to clinicopathological characteristics. The here identified miRNA markers, miR-122 and the miR-200 family members, could be of use in the development of a multi-marker blood test for CRC prognosis.
AB - Circulating microRNAs (miRNAs) have been proposed as minimally invasive prognostic markers for various types of cancers, including colorectal cancer (CRC), the third most diagnosed cancer worldwide. We aimed to evaluate the levels of circulating miRNAs that might serve as markers for CRC prognosis and survival. We included plasma samples of 543 CRC patients with stage I-IV disease from a population-based study carried out in Germany. After comprehensive evaluation of current literature, 95 miRNAs were selected and measured with Custom TaqMan® Array MicroRNA Cards. Plasma samples of non-metastatic and metastatic colon cancer patients, each group consisting of ten patients with 'good' and ten patients with 'bad' prognosis were screened. Identified candidate miRNAs were further validated by RT-qPCR in the whole study cohort. The association of the miRNA levels with patients' survival and the prognostic subtypes was analyzed with uni- and multivariate logistic regression and Cox proportional hazards regression models. Increased miR-122 levels were associated with a 'bad' prognostic subtype in metastatic CRC (Odds ratio: 1.563, 95% confidence interval (CI): 1.038-2.347) and a shorter relapse-free survival and overall survival for non-metastatic (Hazard ratio (HR): 1.370, 95% CI: 1.028-1.825; HR: 1.353, 95% CI: 1.002-1.828) and metastatic (HR: 1.264, 95% CI: 1.050-1.520; HR: 1.292, 95% CI: 1.078-1.548) CRC patients. Additionally, several members of the miR-200 family showed associations with patients' prognosis and correlations to clinicopathological characteristics. The here identified miRNA markers, miR-122 and the miR-200 family members, could be of use in the development of a multi-marker blood test for CRC prognosis.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers, Tumor
KW - Case-Control Studies
KW - Colorectal Neoplasms
KW - Female
KW - Germany
KW - Humans
KW - Male
KW - MicroRNAs
KW - Middle Aged
KW - Multigene Family
KW - Neoplasm Metastasis
KW - Prognosis
KW - Survival Analysis
KW - Journal Article
U2 - 10.1002/ijc.30433
DO - 10.1002/ijc.30433
M3 - SCORING: Journal article
C2 - 27632639
VL - 140
SP - 176
EP - 187
JO - INT J CANCER
JF - INT J CANCER
SN - 0020-7136
IS - 1
ER -